Morgan Stanley Begins Coverage on Immix Biopharma (NASDAQ:IMMX)

Morgan Stanley initiated coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a report issued on Wednesday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $20.00 price target on the stock. Morgan Stanley’s price objective indicates a potential upside of 133.37% from the company’s current price.

A number of other analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Citizens Jmp assumed coverage on shares of Immix Biopharma in a research note on Monday, March 9th. They issued an “outperform” rating and a $23.00 price target on the stock. Wall Street Zen cut shares of Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Finally, Mizuho began coverage on shares of Immix Biopharma in a research report on Monday, February 9th. They set an “outperform” rating and a $14.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Immix Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $16.25.

Immix Biopharma Price Performance

Shares of Immix Biopharma stock opened at $8.57 on Wednesday. The company has a market capitalization of $453.87 million, a P/E ratio of -11.13 and a beta of 0.25. The business has a 50-day moving average of $7.54 and a two-hundred day moving average of $5.15. Immix Biopharma has a 1 year low of $1.34 and a 1 year high of $11.61.

Hedge Funds Weigh In On Immix Biopharma

Large investors have recently bought and sold shares of the company. Allworth Financial LP acquired a new position in Immix Biopharma during the 4th quarter worth approximately $30,000. Mathes Company Inc. acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at approximately $56,000. Balyasny Asset Management L.P. bought a new stake in shares of Immix Biopharma in the fourth quarter worth $67,000. Kera Capital Partners Inc. bought a new stake in shares of Immix Biopharma in the fourth quarter worth $68,000. Finally, Squarepoint Ops LLC acquired a new position in Immix Biopharma during the fourth quarter worth $112,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.